Posted by Michael Wonder on 25 Sep 2024
Lilly's Kisunla (donanemab-azbt) approved in Japan for the treatment of early symptomatic Alzheimer's disease
24 September 2024 - Japan is the second major market where Kisunla has received approval.
The Ministry of Health, Labour and Welfare Japan has approved Kisunla (donanemab-azbt, 350 mg/20 mL every four weeks injection for intravenous infusion), Eli Lilly's Alzheimer's treatment for adults with early symptomatic Alzheimer's disease, which includes people with mild cognitive impairment as well as people with the mild dementia stage of AD, with confirmed amyloid pathology.
